Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 2, 2002 - Issue 5
Submit an article Journal homepage
183
Views
39
CrossRef citations to date
0
Altmetric
Miscellaneous

IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside

Robert H Wiltrout Laboratory of Experimental Immunology, Center f or Cancer Research, National Cancer Institute, Frederick, MD, USA
&
Jon M Wigginton Investigational Biologics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA, Tel: +1 301 846 5468; Fax: +1 301 846 1673;, E-mail: [email protected]
Pages 513-524 | Published online: 23 Feb 2005

Bibliography

  • KOBAYASHI M, FITZ L, RYAN M et al.: Identification, and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. I Exp. Med. (1989) 170:827–845.
  • WOLF SF, TEMPLE PA, KOBAYASHI M et, al: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. Innnunoi (1991) 146:3074–3081.
  • STERN AS, PODLASKI FJ, HULMES JD et al: Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Nati Acad. Sci. USA (1990) 87:6808–6812.
  • GUBLER U, CHUA AO, SCHOENHAUT DS et al.: Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc. Nati Acad. Sci. USA (1991) 88:4143–4147.
  • TRINCHIERI G: Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol (1998) 70:83–243.
  • CHAN SH, PERUSSIA B, GUPTA JW et al.: Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. I Exp. Med (1991) 173:869–879.
  • BRUNDA MJ, LUISTRO L, WARRIER RR et al.: Antitumour and antimetastatic activity of interleukin-12 against murine tumours. Exp. Med. (1993) 178:1223–1230.
  • NASTALA CL, EDINGTON HD, MCKINNEY TG et al: Recombinant IL-12 administration induces tumour regression in association with IFN-gamma production. Immunol. (1994) 153:1697–1706.
  • NOGUCHI Y, JUNGBLUTH A, RICHARDS EC, OLD LJ: Effect of interleukin-12 on tumour induction by 3-methylcholanthrene. Proc. Nati Acad. Sci. USA (1996) 93:11798–11801.
  • CAMINSCHI I, VENETSANAKOS E, LEONG CC, GARLEPP MJ, SCOTT B, ROBINSON BW: Interleukin-12 induces an effective antitumour response in malignant mesothelioma. Am. I Respit Cell Moi Biol. (1998) 19:738–746.
  • CUI J, SHIN T, KAWANO T et al.: Requirement, for Valphal4 NKT cells in IL- 12-mediated rejection of tumours. Science (1997) 278: 1623-1626.
  • HARADA M, TAMADA K, ABE K et al.:Systemic administration of interleukin-12 can restore the antitumour potential of B16 melanoma-draining lymph node cells impaired at a late tumour-bearing state. mt. J. Cancer (1998) 75:400–405.
  • HARADA M, TAMADA K, ABE K, YASUMOTO K, KIMURA G, NOMOTO K: Role of the endogenous production of interleukin-12 in immunotherapy. Cancer Res. (1998) 58:3073–3077.
  • BRUNDA MJ, LUISTRO L, HENDRZAK JA, FOUNTOULAKIS M, GAROTTA G, GATELY MK: Role of interferon-gamma in mediating the antitumour efficacy of interleukin-12. I Immunother Emphasis Tumour Immunol (1995) 17:71–77.
  • TANNENBAUM CS, TUBBS R, ARMSTRONG D, FINKE JH, BUKOWSKI RM, HAMILTON TA: The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumour. I Immunol. (1998) 161:927–932.
  • TANNENBAUM CS, WICKER N, ARMSTRONG D et al.: Cytokine and chemokine expression in tumours of mice receiving systemic therapy with IL-12.j Immunol (1996) 156:693–699.
  • DIAS S, THOMAS H, BALKWILL F: Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. Int. J. Cancer (1998) 75:151–157.
  • FALLARINO F, UYTTENHOVE C, BOON T, GAJEWSKI TF: Endogenous IL-12 is necessary for rejection of P815 tumour variants in vivo. I Immunol (1996) 156:1095–1100.
  • CAVALLO F, DI CARLO E, BUTERA M et al.: Immune events associated with the cure of established tumours and spontaneous metastases by local and systemic interleukin-12. Cancer Res. (1999) 59:414–421.
  • TAKEDA K, SEKI S, OGASAWARA K et al.: Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumour metastasis. Immunol. (1996) 156:3366–3373.
  • YU WG, OGAWA M, MU Jet al.: IL-12-induced tumour regression correlates with in situ activity of IFN-gamma produced by tumour-infiltrating cells and its secondary induction, of antitumour pathways..! Leukoc. Biol (1997) 62:450–457.
  • MU J, ZOU JP, YAMAMOTO N et al.: Administration of recombinant interleuldn-12 prevents outgrowth of tumour cells metastasizing spontaneously to lung and lymph nodes. Cancer Res. (1995) 55:4404–4408.
  • HUNTER SE, WALDBURGER KE, THIBODEAUX DK, SCHAUB RG, GOLDMAN SJ, LEONARD JP: Immunoregulation by interleukin-12 in MB49.1 tumour-bearing mice: cellular and cytokine-mediated effector mechanisms. Lim Immunol, (1997) 27:438–446.
  • VERBIK DJ, STINSON WW, BRUNDA MJ, KESSINGER A, JOSHI SS: In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma. Clin. Exp. Metastasis (1996) 14:219–229.
  • KISHIMA H, SHIMIZU K, MIYAO Y et al.: Systemic interleukin-12 displays antitumour activity in the mouse central nervous system. Br. Cancer (1998) 78:446–453.
  • JEAN WC, SPELLMAN SR, WALLENFRIEDMAN, MA, HALL WA, LOW WC: Interleukin-12-based immunotherapy against rat 9L glioma. Neurosurgery (1998) 42:850–856.
  • VIZLER C, ROSATO A, CALDERAZZO F,et al.: Therapeutic effect of interleukin-12 on mouse haemangiosarcomas is not associated with an increased antitumour cytotoxic T lymphocyte activity. Br. Cancer (1998) 77:656–662.
  • WATANABE M, MCCORMICK KL, VOLKER K et al.: Regulation of local host-mediated antitumour mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis. Am. Pathol, (1997) 150:1869–1880.
  • COUGHLIN CM, SALHANY KE, GEE MS et al.: Tumour cell responses to IFN-gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity (1998) 9:25–34.
  • MAYOR SE, O& DONNELL MA, CLINTON SK: Interleuldn-12 (IL-12) immunotherapy of experimental bladder cancer. Proc. Am. Assoc. Cancer Res (1994) 35:474.
  • HASHIMOTO W, OSAKI T, OKAMURA H et al.: Differential antitumour effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand. Immunol (1999) 163:583–589.
  • KODAMA T, TAKEDA K, SHIMOZATO 0 et al: Perform-dependent NK cell cytotoxicity is sufficient for anti metastatic effect of IL-12. Eur. Immunol (1999) 29:1390–1396.
  • BOGGIO K, NICOLETTI G, DI CARLO E et al: Interleukin-12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice.' Exp. Med. (1998) 188:589–596.
  • BOGGIO K, DI CARLO E, ROVERO S et al.: Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neutransgenic mice. Cancer Res. (2000) 60:359–364.
  • KAPLAN DH, SHANKARAN V, DIGHE AS et al.: Demonstration of an interferon gamma-dependent tumour surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci USA (1998) 95:7556–7561.
  • SCHILLER JH, PUGH M, KIRKWOOD JM, KARP D, LARSON M, BORDEN E: Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin. Cancer Res. (1996) 2:29–36.
  • KIM CJ, TAUBENBERGERJK, SIMONIS TB, WHITE DE, ROSENBERG SA, MARINCOLA FM: Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma. Immunother. Emphasis Tumour Immunol (1996) 19:50–58.
  • GOLLOB JA, SCHNIPPER CP, ORSINI Eet al.: Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.1 Clin. Invest. (1998) 102:561–575.
  • VOEST EE, KENYON BM, O'REILLY MS, TRUITT G, D'AMATO RJ, FOLKMAN J: Inhibition of angiogenesis in vivoby interleukin-12.1 Natl. Cancer Inst (1995) 87:581–586.
  • SGADARI C, ANGIOLILLO AL, TOSATO G: Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood (1996) 87:3877–3882.
  • COUGHLIN CM, SALHANY KE, WYSOCKA M et al.: Interleuldn-12 and interleukin-18 synergistically induce murine tumour regression which involves inhibition of angiogenesis. Clin. Immunol (1998) 101:1441–1452.
  • YAO L, SGADARI C, FURUKE K, BLOOM ET, TERUYA-FELDSTEIN J, TOSATO G: Contribution of natural killer cells, to inhibition of angiogenesis by interleukin-12. Blood (1999) 93: 1612-1621.
  • ATKINS MB, ROBERTSON MJ, GORDON M et al.: Phase I evaluation of intravenous recombinant human interleukin-12 in patients with advanced malignancies. Clin. Cancer Res. (1997) 3:409–417.
  • BUKOWSKI RM, RAYMAN P, OLENCKI T et al.: Interleukin-12 (IL-12) administration to patients with renal cell carcinoma: effects on cytokine gene expression in peripheral blood, skin and tumour. PrOC. Am. Soc. Clin. Oncol (1996) 15:354.
  • MOTZER RJ, RAKHIT A, SCHWARTZ LH et al.: Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. Cancer Res. (1998) 4:1183–1191.
  • PORTIELJE JE, KRUIT WH, SCHULER M, et al.: Phase I study of subcutaneously administered recombinant human interleukin-12 in patients with advanced renal cell cancer. Clin. Cancer Res. (1999) 5:3983–3989.
  • GOLLOB JA, MIER JW, VEENSTRA K et al.: Phase I trial of twice-weekly intravenous interleukin-12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin. Cancer Res. (2000) 6:1678–1692.
  • LEONARD JP, SHERMAN ML, FISHER GL et al.: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 90:2541–2548.
  • SUN Y, JURGOVSKY K, MOLLER P et al.: Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical Phase I study. Gene The]: (1998) 5:481–490.
  • BACON CM, MCVICAR DW, ORTALDO JR, REES RC, O'SHEA JJ, JOHNSTON JA: Interleukin-12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12.1. Exp. Med (1995) 181:399–404.
  • GOLLOB JA, SCHNIPPER CP, MURPHY EA, RITZ J, FRANK DA: The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. I Immunol (1999) 162:4472–4481.
  • DESAI BB, QUINN PM, WOLITZKY AG, MONGINI, PK, CHIZZONITE R, GATELY MK: IL-12 receptor. II. Distribution and regulation of receptor expression. I Immunol (1992) 148:3125–3132.
  • YANAGIDA T, KATO T, IGARASHI 0, INOUE T, NARIUCHI H: Second signal activity of IL-12 on the proliferation and IL-2R expression of T helper cell-1 clone. Immunol (1994) 152:4919–4928.
  • NGUYEN T, WANG R, RUSSELL JH: IL-12 enhances IL-2 function by inducing CD25 expression through a p38 mitogen-activated protein kinase pathway. Ear: Immunol (2000) 30:1445–1452.
  • WANG KS, FRANK DA, RITZ J: Interleukin-2 enhances the response of natural killer cells to interleukin-12 through upregulation of the interleukin-12 receptor and STAT4. Blood (2000) 95:3183–3190.
  • BERTAGNOLLI MM, LIN BY, YOUNG D,, HERRMANN SH: IL-12 augments antigen-dependent proliferation of activated T lymphocytes. I Immunol (1992) 149:3778–3783.
  • DE JONG R, JANSON AA, FABER WR,NAAFS B, OTTENHOFF TH: IL-2 and IL-12 act in synergy to overcome antigen-specific T cell unresponsiveness in mycobacterial disease. I Immunol (1997) 159:786–793.
  • GATELY MK, DESAI BB, WOLITZKY AG et al.: Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). Immunol, (1991) 147:874–882.
  • PERUSSIA B, CHAN SH, D'ANDREA A et al.: Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes and NK cells. Immunol, (1992) 149:3495–3502.
  • ASTE-AMEZAGA M, D'ANDREA A, KUBIN M, TRINCHIERI G: Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell Immunol (1994) 156:480–492.
  • YE J, ORTALDO JR, CONLON K, WINKLER-PICKETT R, YOUNG HA: Cellular and molecular mechanisms of IFN-gamma production induced by IL-2 and IL-12 in a human NK cell line. I Leukoc. Biol. (1995) 58:225–233.
  • CHAN SH, KOBAYASHI M, SANTOLI D, PERUSSIA B, TRINCHIERI G: Mechanisms, of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. j. Immunol (1992) 148:92–98.
  • MARZUSCH K, BUCHHOLZ F, RUCK P et al.: Interleukin-12- and interleukin-2-stimulated release of interferon-gamma by uterine CD56++ large granular lymphocytes is, amplified by decidual macrophages. Hum. Reprod. (1997) 12:921–924.
  • MEHROTRA PT, DONNELLY RP, WONG S et al.: Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. Immunol (1998) 160:2637–2644.
  • JEANNIN P, DELNESTE Y, SEVESO M, LIFE P, BONNEFOY JY: IL-12 synergizes with IL-2 and other stimuli in inducing IL-10 production by human T cells. I Immunol (1996) 156:3159–3165.
  • GATELY MK, WILSON DE, WONG HL: Synergy between recombinant interleukin-2 (rIL 2) and IL 2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro.' Immunol (1986) 136:1274–1282.
  • DEBLAKER-HOHE DF, YAMAUCHI A, YU CR, HORVATH-ARCIDIACONO JA, BLOOM ET: IL-12 synergizes with IL-2 to induce lymphokine-activated cytotoxicity and perforin and granzyme gene expression in fresh human NK cells. Cell Immunol (1995) 165:33–43.
  • FACCHETTI P, TACCHETTI C, PRIGIONE I et al.: Ultrastructural and functional studies of the interaction between IL-12 and IL-2 for the generation of lymphokine-activated killer cells. Exp. Cell Res. (1999) 253:440–453.
  • SATOH M, SEKI S, HASHIMOTO W et al.: Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. Immunol (1996) 157:3886–3892.
  • RODELLA L, REZZANI R, ZAULI G, MARIANI AR, RIZZOLI R, VITALE M: Apoptosis induced by NK cells is modulated by the NK-active cytokines IL-2 and IL-12. hat. Immunol (1998) 10:719–725.
  • MEHROTRA PT, WU D, CRIM JA, MOSTOWSKI HS, SIEGEL JP: Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. j. Immunol (1993) 151:2444–2452.
  • HODGE DL, MARTINEZ A, JULIAS JG,TAYLOR LS, YOUNG HA: Regulation of nuclear gamma interferon gene expression by interleukin-12 (IL-12) and IL-2 represents a novel form of post-transcriptional control. Ma, Cell Biol. (2002) 22:1742–1753.
  • VITALE A, GUARINI A, LATAGLIATA R, CIGNETTI A, FOA R: Cytotoxic effectors activated by low-dose IL-2 plus IL-12 lyse IL-2-resistant autologous acute myeloid leukaemia blasts. Br. Haematol (1998) 101:150–157.
  • RASHLEIGH SP, KUSHER DI, ENDICOTT JN, ROSSI AR, DJEU JY: Interleukins 2 and 12 activate natural killer cytolytic responses of peripheral blood mononuclear cells from patients with head and neck squamous cell carcinoma. Arch. Otolaryngol Head Neck Surg. (1996) 122:541–547.
  • CHEN YM, YANG WK, TING CC et al:Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients. Chest (1997) 112:960–966.
  • BARTON DP, BLANCHARD DK, DUAN C, et al.: Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid. I Soc. Cynecol Investig. (1995) 2:762–771.
  • DECESARE SL, MICHELINI-NORRIS B, BLANCHARD DK et al.: Interleuldn-12- mediated, tumouricidal activity of patient lymphocytes in an autologous in vitro ovarian cancer assay system. Cynecol Oncol (1995) 57:86–95.
  • ROSSI AR, PERICLE F, RASHLEIGH S, JANIEC J, DJEU JY: Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood(1994) 83:1323–1328.
  • MARIANI E, MENEGHETTI A, TAROZZI A, CATTINI L, FACCHINI A: Interleukin-12 induces efficient lysis of natural killer-sensitive and natural killer-resistant human osteosarcoma cells: the synergistic effect of interleukin-2. Scand. .1 Immunol (2000) 51:618–625.
  • UHAREK L, ZEIS M, GLASS B et al: High lytic activity against human leukaemia cells after activation of allogeneic NK cells by IL-12 and IL-2. Leukaemia (1996) 10: 1758-1764.
  • ZEH HJ, HURD S, STORKUS WJ, LOTZE MT: Interleuldn-12 promotes the proliferation, and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. .1 Immunother. (1993) 14:155–161.
  • KOYAMA S: Augmented human-tumour-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumour culture activated by interleukin-12 plus interleukin-2 and the phenotypic characterization of the cells in patients with advanced carcinoma. .1 Cancer Res. Gin. Oncol (1997) 123:478–484.
  • LEHMANN C, ZEIS M, UHAREK L: Activation of natural killer cells with interleukin-2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells. Br. .1 Haematol (2001) 114:660–665.
  • ANDREWS JV, SCHOOF DD, BERTAGNOLLI MM, PEOPLES GE, GOEDEGEBUURE PS, EBERLEIN TJ: Immunomodulatory effects of interleukin-12 on human tumour-infiltrating lymphocytes. Inonunother,. (1993) 14:1–10.
  • STEGER GG, GNANT ME DJAVANMARD, MP et al.: The in vitro effects of interleukin-12 upon tumour-infiltrating lymphocytes derived from renal cell carcinoma. .1 Cancer Res. Gin. Oncol (1997) 123:317–324.
  • HANAGIRI T, TAKENOYAMA M, YOSHIMATSU T et al.: Effects of interleukin-12 on in vitro culture with interleukin-2 of regional lymph node lymphocytes from lung cancer patients. Cancer, Immunol Innnunother. (1996) 43:87–93.
  • RAKHIT A, YEON MM, FERRANTE J et al.: Downregulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this 'adaptive response' in mice. Clin. Pharmacol The,: (1999) 65:615–629.
  • ULCHAKER J, PANUTO J, RAYMAN Pet al.: Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12.J. Inonunother. (1999) 22:71–79.
  • WIGGINTON JM, KOMSCHLIES KL, BACK TC, FRANCO JL, BRUNDA MJ, WILTROUT RH: Administration of interleukin-12 with pulse interleukin-2 and the rapid and complete eradication of murine renal carcinoma. Natl. Cancer Inst (1996) 88:38–43.
  • WIGGINTON JM, PARK JW, GRUYS ME et al.: Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression and mammary epithelial apoptosis. Immunol (2001) 166:1156–1168.
  • MAROULAKOU IG, ANVER M, GARRETT L, GREEN JE: Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumour antigen fusion gene. Proc. Natl. Acad. Sci USA (1994) 91:11236–11240.
  • ANGIOLILLO AL, SGADARI C, TAUB DD et al.: Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. j Exp. Med. (1995) 182:155–162.
  • STRIETER RM, KUNKEL SL, ARENBERG DA, BURDICK MD, POLVERINI PJ: Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. (1995) 210:51–57.
  • STRIETER RM, POLVERINI PJ, KUNKEL SL et al.: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis." Biol. Chem (1995) 270:27348–27357.
  • WIGGINTON JM, GRUYS E, GEISELHART L et al.: IFN-gamma and Fas/FasL are required for the antitumour and antiangiogenic effects of IL-12/pulse IL-2 therapy.j Clin. Invest. (2001) 108:51–62.
  • LID, SHUGERT E, GUO M, BISHOP JS, O,'MALLEY BW JR: Combination nonviral interleukin-2 and interleukin-12 gene therapy for head and neck squamous cell carcinoma. Arch. Otolaryngol Head Neck Surg. (2001) 127:1319–1324.
  • ADDISON CL, BRAMSON JL, HITT MM, MULLER WJ, GAULDIE J, GRAHAM FL: Intratumoural coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumours. Gene Ther (1998) 5:1400–1409.
  • KIKUCHI T, JOKI T, SAITOH S et al.: Antitumour activity of interleukin-2-producing tumour cells and recombinant interleukin-12 against mouse glioma cells located in the central nervous system. Int. J. Cancer (1999) 80:425–430.
  • KIKUCHI T, JOKI T, AKASAKI Y, ABE T, OHNO T: Antitumour activity of interleukin-12 against interleukin-2-transduced mouse glioma cells. Cancer Lett. (1999) 135:47–51.
  • VAGLIANI M, ROD OLFO M, CAVALLO F et al.: Interleukin-12 potentiates the curative effect of a vaccine based on interleukin-2-transduced tumour cells. Cancer Res. (1996) 56:467–470.
  • PAPPO I, TAHARA H, ROBBINS PD et al: Administration of systemic or local interleukin-2 enhances the anti tumour effects of interleukin-12 gene therapy.' Surg. Res. (1995) 58:218–226.
  • ZITVOGEL L, TAHARA H, ROBBINS PD et al.: Cancer immunotherapy of established tumours with IL-12. Effective delivery by genetically engineered fibroblasts. Immunol, (1995) 155:1393–1403.
  • TANAKA M, SAIJO Y, SATO G et al.: Induction of antitumour immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma. Cancer Gene The,: (2000) 7:1481–1490.
  • TAKADA T, KATO K, YAGITA H, HAMADA H, OKUMURA K: Effects of immunization with tumour cells double transfected with interleukin-2 (IL-2) and interleukin-12 (IL-12) genes on artificial metastasis of colon26 cells in BALB/c mice. Gin. Exp. Metastasis (1999) 17:125–130.
  • LODE HN, XIANG R, DUNCAN SR, THEOFILOPOULOS AN, GILLIES SD, REISFELD RA: Tumour-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc. Natl. Acad. Sci. USA (1999) 96:8591–8596.

Websites

  • http://www.cancer.gov/search/clinical_trials National Cancer Institute - Physician data query website.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.